Recent Advances in the Treatment and Management of Non-Small Cell Lung Cancer (NSCLC): Managed Care Perspectives for Improved Patient Outcomes

Recent Advances in the Treatment and Management of Non-Small Cell Lung Cancer (NSCLC): Managed Care Perspectives for Improved Patient Outcomes is organized by National Association of Managed Care Physicians (NAMCP).,This activity is valid from August 1, 2022, to August 1, 2023,Description:,Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers, and during 2020, it was expected that there were about 228,820 new cases of lung cancer. Non-small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there were an estimated 135,720 deaths from lung cancer in 2020, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. As more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on the unique characteristics of their cancer. Healthcare professionals (HCPs) need to be aware of information regarding tumor-specific diagnosis, expanding treatment options, and supporting data to maximize the care of their patients.,Upon completion of this activity, participants will be able to:,• Assess the clinical and economic burden of non-small cell lung cancer (NSCLC) in terms of relative survival, mortality, drug utilization, adverse event management, and hospitalizations,• Delineate tumor tissue testing and liquid biopsy strategies that should be undertaken prior to frontline treatment and in relapsed NSCLC settings to inform clinical decision-making among patients with EGFR, KRAS, and MET alterations,• Analyze recent safety and efficacy data on single-agent or combination strategies with targeted agents, including EGFR, KRAS, and MET inhibitors, for the treatment of NSCLC,• Discuss the evolving role of immunotherapy, both alone and in combination, for patients with advanced NSCLC,• Evaluate effective strategies to proactively counsel and manage adverse events associated with targeted therapies, including EGFR, KRAS, and MET inhibitors, in the treatment of patients with metastatic NSCLC,• Examine managed care considerations to facilitate optimal use of targeted therapies, including EGFR, KRAS, and MET inhibitors, in advanced NSCLC,Additional details will be posted as soon as information is available.